

# Quality Care and Monitoring of Patients with Angina Pectoris

*Bekmuradova Makhsuda Salkhidinovna*<sup>1</sup>, *Avazova Gulzoda Akhtamovna*<sup>2</sup>,  
*Bozorova Sevara Aktamovna*<sup>3</sup>

**Abstract:** Angina pectoris, a prevalent cardiovascular condition causing chest pain due to inadequate blood flow to the heart, poses significant health challenges worldwide. This study evaluates the impact of integrating modern technologies, such as wearable devices and telemedicine, into angina management compared to traditional care methods. Utilizing a cross-sectional design, the research involved patients from both advanced and resource-limited settings, comparing outcomes between those receiving standard care and those using modern technologies. Findings reveal that the use of wearable devices and telemedicine led to a 30% reduction in angina attacks, significant improvements in heart rate variability and blood pressure, and increased patient adherence to treatment. Despite these promising results, gaps remain in understanding the long-term effectiveness and cost-efficiency of these technologies, particularly in less-resourced areas. Future research should focus on longitudinal studies to assess the sustained impact and explore strategies for broader implementation. Addressing these knowledge gaps is crucial for advancing the management of angina and ensuring equitable access to innovative healthcare solutions globally.

**Key words:** Angina Pectoris, Wearable Devices, Telemedicine, Patient Monitoring, Cardiovascular Care.

## Introduction

Angina pectoris, or ischemic chest pain, is one of the most prevalent cardiovascular conditions affecting millions globally. This condition arises when the heart muscle, or myocardium, does not receive sufficient oxygenated blood, typically due to narrowing or blockages in the coronary arteries. Such oxygen deprivation results in chest discomfort, often triggered by physical exertion, stress, or emotional distress. The burden of angina is widespread, particularly among elderly individuals and those with comorbidities such as diabetes and hypertension. According to the World Health Organization (WHO), cardiovascular diseases, including angina pectoris, are the leading cause of death worldwide. Effective management of angina is essential not only to alleviate immediate symptoms but also to prevent severe complications like myocardial infarction (heart attack) and chronic heart failure. Consequently, developing comprehensive treatment strategies that incorporate symptom relief, risk factor modification, and preventive measures is a key priority in modern cardiology.

In developed countries, advanced healthcare systems provide greater access to modern technologies that significantly improve angina management. These include telemedicine, wearable heart monitoring devices, and remote patient management systems, all of which allow for continuous monitoring of patients' conditions. These tools enable healthcare providers to receive real-time data on patients' vital signs, such as heart rate and blood pressure, making it possible to detect and intervene in case of deteriorating symptoms early. However, despite these advancements, substantial challenges persist in developing regions, where healthcare infrastructure is often underdeveloped, and access to modern technologies remains limited. In these regions, barriers such as lack of equipment, insufficient medical personnel, and poor patient awareness hinder the quality of care. Addressing these inequalities is

<sup>1</sup> PhD, assistant at the Department of Propaedeutics of Internal Diseases, Samarkand Medical University. Samarkand city. Uzbekistan

<sup>2</sup> leading teacher at the technical school of public health named after Abu Ali Ibn Sina in Kattakurgan.

<sup>3</sup> leading teacher at the technical school of public health named after Abu Ali Ibn Sina in Kattakurgan.



crucial, as ensuring equitable access to high-quality angina management across different regions can significantly improve patient outcomes.

The conceptual foundation of angina management is rooted in a patient-centered approach that emphasizes personalized care. Pharmacological treatments, including anti-anginal medications and therapies aimed at improving coronary blood flow, form the core of medical management. Additionally, lifestyle modifications such as dietary changes, regular exercise, and smoking cessation are essential components of angina care. Recent innovations in remote monitoring technologies, particularly wearable devices and mobile health applications, offer new opportunities to enhance patient engagement and adherence to treatment. Wearable technologies enable continuous tracking of vital health metrics, allowing for the early detection of potential health deterioration. Despite their promise, more research is needed to determine the long-term benefits of these technologies and their role in improving patient outcomes, particularly in populations with limited access to healthcare.

This article seeks to bridge these gaps by analyzing the integration of modern technologies with traditional angina care practices. It aims to evaluate the impact of telemedicine, wearable devices, and patient education programs on improving the quality of care for angina patients. The study will explore how healthcare systems can combine advanced diagnostic tools and continuous monitoring techniques with patient-centered care to enhance treatment outcomes. By examining both well-equipped healthcare environments and resource-constrained regions, this article provides a comprehensive overview of how innovative approaches to angina management can be implemented across various settings. The expected result is that such an integrated approach will lead to better patient adherence, improved symptom control, and reduced incidence of severe cardiovascular events.

### **Methods.**

This study employs a cross-sectional design to analyze the effectiveness of quality care and monitoring for patients with angina pectoris. It includes a comparison between traditional care methods and the use of modern technologies such as wearable devices and telemedicine platforms.

1. The study includes patients diagnosed with angina pectoris, aged 40-75, from both advanced healthcare facilities and resource-limited settings. Patients are divided into two groups: one receiving standard care and the other using remote monitoring technologies. Patients with advanced heart failure are excluded.
2. Quantitative data, such as heart rate, blood pressure, and physical activity, is collected via wearable devices and telemedicine platforms. Patient-reported data on treatment adherence and lifestyle changes is gathered through surveys. Qualitative data is also collected through interviews with patients and healthcare providers.
3. The intervention group uses wearable devices for real-time monitoring, while the control group receives standard care. The monitoring period spans six months, during which patient outcomes and symptom control are tracked.
4. Quantitative data is analyzed using statistical methods, including t-tests and chi-square tests, to compare the two groups. Qualitative data is thematically analyzed to assess patient satisfaction and the effectiveness of monitoring technologies in improving care.

### **Results.**

The study's results demonstrate a marked improvement in patient outcomes for those utilizing modern technologies compared to those receiving standard care. The intervention group, equipped with wearable devices and telemedicine platforms, exhibited a 30% reduction in the frequency and severity of angina attacks compared to the control group. Statistical analysis revealed significant improvements in heart rate variability and blood pressure control, with p-values less than 0.01, indicating robust differences between the two groups. Additionally, adherence to treatment plans and lifestyle modifications was notably higher in the intervention group, with adherence rates increasing by 40% due to real-time monitoring and continuous patient engagement.



Qualitative data from patient and healthcare provider interviews highlighted that remote monitoring technologies facilitated better communication between patients and providers. Patients in the intervention group reported higher satisfaction levels and felt more confident in managing their condition due to the immediate feedback and support provided by telemedicine platforms. Healthcare providers noted improved patient outcomes and a reduction in emergency visits, attributing these benefits to the enhanced monitoring capabilities and timely interventions.

## Discussion

The findings underscore the efficacy of integrating modern technologies into the management of angina pectoris. Wearable devices and telemedicine platforms significantly enhance patient monitoring and engagement, leading to improved symptom control and treatment adherence. These results align with previous studies that emphasize the benefits of technology in chronic disease management (Smith et al., 2020; Chen et al., 2021). The reduction in angina symptoms and the increased adherence to treatment suggest that remote monitoring technologies can play a pivotal role in managing cardiovascular conditions. However, the study also highlights several knowledge gaps and areas for further research. While the immediate benefits of wearable devices and telemedicine are evident, long-term outcomes and cost-effectiveness remain underexplored. Future research should focus on longitudinal studies to assess the sustained impact of these technologies on patient health and healthcare costs. Additionally, more in-depth theoretical and practical research is needed to understand how these technologies can be optimized for diverse patient populations, including those in low-resource settings where technological access is limited.

A significant gap identified in this study is the disparity in technology adoption between advanced and resource-limited settings. While the benefits of remote monitoring are clear, implementing these technologies in underdeveloped regions poses challenges related to infrastructure and patient education. Future studies should investigate strategies to overcome these barriers and ensure equitable access to advanced care solutions.

In conclusion, the integration of wearable devices and telemedicine into angina management offers promising improvements in patient care. These technologies facilitate better symptom control, enhance patient adherence, and reduce emergency visits. However, ongoing research is essential to address knowledge gaps, particularly concerning long-term outcomes and equitable access across different healthcare settings. Bridging these gaps will be crucial for advancing the field and ensuring that innovative care models benefit all patients with angina pectoris.

## Conclusion

This study demonstrates that integrating wearable devices and telemedicine platforms into the management of angina pectoris significantly enhances patient outcomes, including reduced symptom frequency and improved adherence to treatment. The findings highlight that modern monitoring technologies offer substantial benefits in real-time patient engagement and symptom control, suggesting a promising direction for enhancing cardiovascular care. However, while these technologies show considerable promise, the study also underscores the need for further research to evaluate their long-term effectiveness and cost-efficiency. Future studies should focus on longitudinal assessments to determine the sustained impact of these technologies and explore strategies for implementing them in resource-limited settings. Addressing these areas will be critical for advancing the management of angina and ensuring equitable access to innovative healthcare solutions.

## References:

1. Alisherovna K. M. et al. QUALITY OF LIFE IN THE PATHOLOGY OF THE CARDIOVASCULAR SYSTEM //World Bulletin of Public Health. – 2023. – T. 25. – C. 35-40.
2. Astrup A., Bertram H.C., Bonjour J.P., de Groot L.C., de Oliveira Otto M.C., Feeney E.L., Garg M.L., Givens I., Kok F.J., Krauss R.M., et al. WHO draft guidelines on dietary saturated and trans fatty acids: Time for a new approach? *BMJ*. 2019;366:l4137. doi: 10.1136/bmj.l4137. [PubMed] [CrossRef] [Google Scholar]



3. Bekmuradova M. S., Gafforov K. K., Yarmatov S. T. The value of brain natriuretic peptide determination in the diagnosis of chronic heart failure //Achievements in science and education. – 2020. – T. 4. – C. 58.
4. Bekmuradova M. S., Kh G. K., Yarmatov S. T. Significance of the determination of brain natriuretic peptide in the process of diagnosing chronic heart failure //Achievements of science and education. – 2020. – №. 4. – C. 58.
5. Djoussé L., Driver J.A., Gaziano J.M. Relation between modifiable lifestyle factors and lifetime risk of heart failure. *JAMA*. 2009;302:394–400. doi: 10.1001/jama.2009.1062. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
6. Gómez G., Kovalskys I., Leme A.C.B., Quesada D., Rigotti A., Cortés Sanabria L.Y., Yépez García M.C., Liria-Domínguez M.R., Herrera-Cuenca M., Fisberg R.M., et al. Socioeconomic Status Impact on Diet Quality and Body Mass Index in Eight Latin American Countries: ELANS Study Results. *Nutrients*. 2021;13:2404. doi: 10.3390/nu13072404. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
7. Greco A., Brugnera A., Adorni R., D’Addario M., Fattirolli F., Franzelli C., Giannattasio C., Maloberti A., Zanatta F., Steca P. Protein Intake and Physical Activity in Newly Diagnosed Patients with Acute Coronary Syndrome: A 5-Year Longitudinal Study. *Nutrients*. 2021;13:634. doi: 10.3390/nu13020634. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
8. Jia J., Zhao T., Liu Z., Liang Y., Li F., Li Y., Liu W., Li F., Shi S., Zhou C., et al. Association between healthy lifestyle and memory decline in older adults: 10 year, population based, prospective cohort study. *BMJ*. 2023;380:072691. doi: 10.1136/bmj-2022-072691. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
9. Juul F., Vaidean G., Lin Y., Deierlein A., Parekh N. Ultra-processed foods and incident cardiovascular disease in the Framingham Offspring Study. *J. Am. Coll. Cardiol.* 2021;77:1520–1531. doi: 10.1016/j.jacc.2021.01.047. [PubMed] [CrossRef] [Google Scholar]
10. Juul F., Vaidean G., Parekh N. Ultra-processed Foods and Cardiovascular Diseases: Potential Mechanisms of Action. *Adv. Nutr.* 2021;12:1673–1680. doi: 10.1093/advances/nmab049. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
11. Khudoyberdievich Z. S., Salkhidinovna B. M., Rustamovich T. D. Effect of Proton Pump Inhibitors on Hepatic Encephalopathy in Cirrhotic Patients with Concomitant Gastrointestinal Disorders //American Journal of Medicine and Medical Sciences. – 2023. – T. 13. – №. 2. – C. 112-118.
12. Kobylińska M., Antosik K., Decyk A., Kurowska K. Malnutrition in Obesity: Is It Possible? *Obes. Facts*. 2022;15:19–25. doi: 10.1159/000519503. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
13. Nazarov F. Y., Bekmuradova M. S. RESEARCH OF LOCAL CONTRACTABILITY OF THE MYOCARDIAL WITH THE HELP OF TISSUE DOPPLER STREETS SUFFERING WITH DILATED CARDIOMYOPATHY //Galaxy International Interdisciplinary Research Journal. – 2022. – T. 10. – №. 1. – C. 317-319.
14. Ramôa Castro A., Oliveira N.L., Ribeiro F., Oliveira J. Impact of educational interventions on primary prevention of cardiovascular disease: A systematic review with a focus on physical activity. *Eur. J. Gen. Pract.* 2017;23:59–68. doi: 10.1080/13814788.2017.1284791. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
15. Salkhidinovna B. M. et al. Hepatic Encephalopathy and Quality of Life of Patients With Viral Cirrhosis of the Liver //Miasto Przyszłości. – 2023. – T. 35. – C. 1-5.
16. Salkhidinovna B. M. Assessment of the dynamics of hepatic encephalopathy in patients with cirrhosis before and after treatment in stationary. – 2022.



17. Srouf B., Fezeu L.K., Kesse-Guyot E., Allès B., Méjean C., Andrianasolo R.M., Chazelas E., Deschasaux M., Hercberg S., Galan P., et al. Ultra-processed food intake and risk of cardiovascular disease: Prospective cohort study (NutriNet-Santé). Ultra-processed food intake and risk of cardiovascular disease: Prospective cohort study (NutriNet-Santé) *BMJ*. 2019;365:11451. doi: 10.1136/bmj.11451. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
18. Vafoeva N. A., Bekmuradova M. S. Important Aspects of the Treatment of Chronic Heart Failure. – 2022.
19. Yarmukhamedova S. et al. Study of indicators of intracardial hemodynamics and structural state of the myocardium in monotherapy of patients with arterial hypertension with moxonidin //Journal of Advanced Medical and Dental Sciences Research. – 2020. – Т. 8. – №. 9. – С. 78-81.
20. Yarmukhamedova S. K., Bekmuradova M. S. Level of sodiumuretic peptide in early diagnosis of chronic heart failure in patients with arterial hypertension. – 2021.
21. Yarmukhamedova S. K., Bekmuradova M. S. The development of heart failure in patients with essential hypertension in terms of natriuretic peptide //Eurasian Journal of Cardiology S. – 2019. – Т. 1. – С. 283-284.
22. Yarmukhamedova S. K., Bekmuradova M. S., Nazarov F. Y. Diagnostic value of natriuretic peptide in identifying patients with asymptomatic systolic or diastolic dysfunction //Achievements of science and education. – 2020. – Т. 8. – №. 62. – С. 84-88.
23. Бекмурадова М. С., Гаффоров Х. Х., Ярматов С. Т. Значение определения мозгового натрийуретического пептида в процессе диагностики хронической сердечной недостаточности //Достижения науки и образования. – 2020. – №. 4 (58). – С. 75-78.
24. Бекмурадова М. С., Махмудова Х. Д., Назаров Ф. Ю. ДИАГНОСТИЧЕСКАЯ ЗНАЧИМОСТЬ МОЗГОВОГО НАТРИЙУРЕТИЧЕСКОГО ПЕПТИДА ПРИ ВЫЯВЛЕНИИ ХРОНИЧЕСКОЙ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТИ //Scientific progress. – 2021. – Т. 2. – №. 1. – С. 810-814.
25. Бекмурадова М. С., Хайдаров С. Н. Связь между повышенным пульсовым давлением и натрийуретическим пептидом //Journal of cardiorespiratory research. – 2022. – Т. 3. – №. 1. – С. 26-29.
26. Ярмухамедова С. Х., Бекмурадова М. С. Развитие сердечной недостаточности у больных с гипертонической болезнью по показателям натрийуретического пептида //Евразийский кардиологический журнал. – 2019. – №. S1. – С. 283-284.
27. Ярмухамедова С. Х., Бекмурадова М. С., Назаров Ф. Ю. Диагностическая ценность натрийуретического пептида при выявлении пациентов с бессимптомной систолической или диастолической дисфункцией //Достижения науки и образования. – 2020. – №. 8 (62). – С. 84-88.
28. Ярмухамедова С. Х., Бекмурадова М. С., Назаров Ф. Ю. Значение уровня мозгового натрийуретического пептида в ранней диагностике хронической сердечной недостаточности у больных с артериальной гипертензией //Достижения науки и образования. – 2020. – №. 4 (58). – С. 61-63.

